Last reviewed · How we verify
NTX-001
At a glance
| Generic name | NTX-001 |
|---|---|
| Sponsor | Major Extremity Trauma Research Consortium |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion) (PHASE2)
- This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations. (PHASE3)
- NTX-001 to Repair Peripheral Nerve Transection(s)
- Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve Injuries (PHASE2)
- A Study of NTX-001 in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NTX-001 CI brief — competitive landscape report
- NTX-001 updates RSS · CI watch RSS
- Major Extremity Trauma Research Consortium portfolio CI